580 results on '"Graham, Barney S."'
Search Results
2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
3. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery
4. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera
5. Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein
6. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection
7. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase
8. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants
9. Antigen spacing on protein nanoparticles influences antibody responses to vaccination
10. Refined semi-lethal aerosol H5N1 influenza model in cynomolgus macaques for evaluation of medical countermeasures
11. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses
12. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
13. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
14. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses
15. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
16. Functional reconstitution of the MERS CoV receptor binding motif
17. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
18. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination
19. TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination
20. CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns
21. Structure-based design of stabilized recombinant influenza neuraminidase tetramers
22. CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines
23. Stabilized coronavirus spike stem elicits a broadly protective antibody
24. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
25. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection
26. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
27. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses
28. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
29. Quadrivalent influenza nanoparticle vaccines induce broad protection
30. A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies
31. Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020
32. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
33. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
34. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
35. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
36. A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry
37. A Universal Influenza Vaccine : The Strategic Plan for the National Institute of Allergy and Infectious Diseases
38. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
39. Zika Virus Vaccine Development
40. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
41. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
42. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
43. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization
44. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone
45. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
46. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial
47. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection
48. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus
49. Chikungunya in the Americas: Recommendations and Conclusions
50. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.